TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Cord Blood America Announces Early Start to Groundbreaking 'Afford-A-Cord' Program (PR Newswire) Cord Blood America, Inc. , announced today that its groundbreaking "Afford-A-Cord" program, which reduces the initial cost of storing umbilical cord blood stem cells from $2075 to $495 plus medical courier service, will be launched on June 14, 2010 rather than July 1, 2010, as previously announced. us.rd.yahoo.com |
Spectranetics Corp Q2 2010 Earnings Call Transcript Spectranetics Corp (SPNC)Q2 2010 Earnings CallJuly 28, 2010 11:00 am ETComplete Story » seekingalpha.com |
Successful IPOs in Genomics Could Ignite Biotech Stocks Rod Raynovich submits:The IPO market is setting up for continued investor interest in the biotech sector. Two high profile genomics companies, Complete Genomics (GNOM) and Pacific Biosciences (PACB), have filed S-1 Registration Statements with plans to go public in the fourth quarter around the time when market seasonality becomes more bullish. Biotech has been a strong sector in a choppy 2010 market with the NYSE Arca Biotech Index up 15.3% YTD. Selected molecular diagnostics stocks have fared well YTD with GenProbe (GPRO) up 12%, Illumina (ILMN) up 50%, and Sequenom (SQNM) up 44%. Recent data from a Piper Jaffray report in April quantifies the molecular diagnostic market at $4.1B and growing at 12%. Piper sees long term growth coming from genetic testing with pharmacogenomic testing for cancer and sequencing for genetic conditions. Piper believes that lower sequencing costs down below $5000 will enable the convergence into molecular diagnostics.Complete Genomics filed on 7/30 for an $86M IPO with UBS and Jeffries and Co. as underwriters. The Company was founded in 2005, has 159 employees, and has a proprietary DNA sequencing platform with integrated software and bioinformatics providing services for genomic based research (see Raygent profile). Applications for the complete genome sequencing services are cancer research, Mendelian Disease research, Rare Variant Disease research, and clinical trial optimization. The Company has raised $95.4M since inception through six VCs and 5% shareholders: Orbimed Advisors, Essex Woodlands Health Ventures, Prospect Venture Partners III, OVP Venture Partners, Enterprise Partners and Highland Capital Management. The Company has 30 past and current customers for its services including the National Cancer Institute (NCI). Accumulated deficit since inception was $89.6M and revenue for 2010 was $336k with a loss of $14.3M as of 3/31/10. Cash position was $2.4M.Complete Story » seekingalpha.com |
Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock [PR Newswire] - Cannabis Science, Inc. , a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce guidance on its product development and FDA Investigative New Drug Applications for its cannabis clinical trials. us.rd.yahoo.com |
Covance to Present at the Piper Jaffray 22nd Annual Health Care Conference [PR Newswire] - Covance Inc. today announced that it will present at the Piper Jaffray 22nd Annual Health Care Conference on Tuesday, November 30, 2010 at 11:30 a.m. ET. Â Investors may access a live webcast of the presentation at www.covance.com. Â In order to register and download any necessary software, please log on 10 minutes early. us.rd.yahoo.com |